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Cardiopulmonary b pass circuits cause morbidity during cardiac opera- 
tions. Plasma proteins and cellular components are stimulated by contact 
with the cardiopulmonary b pass circuit and can cause bleeding and 
postperfusion syndrome. This is especially true in patients undergoing 
reoperative cardiac procedures, which carries a higher isk of postoperative 
bleeding and prolonged ventilation compared with primary cardiac surgical 
procedures. Recently, cardiopulmonary b pass circuit surfaces have been 
coated with antithrombotic agents to improve their biocompatibility. This 
study evaluated the effect of a heparin-coated cardiopulmonary b pass 
system (Duraflo II, Baxter Bentley Healthcare Systems, Irvine, Calif.) on 
thrombin formation, platelet stimulation, and leukocyte activation in 
patients undergoing reoperative coronary artery bypass grafting or valve 
operation. Fifty patients were selected and randomly assigned to a standard 
noncoated control system (n = 26) or the Duraflo heparin-coated system 
(n = 24). Similar heparin doses were used in both groups (3 mg/kg). The 
heparin-coated group used a completely heparin-coated bypass circuit 
including the cardiotomy reservoir; arterial filters were heparin-coated in 
both groups. Samples were obtained before cardiopulmonary b pass, 30 
minutes into cardiopulmonary b pass, 5minutes after crossclamp removal, 
and 5 minutes after protamine administration. Thrombin formation 
(thrombin-antithrombin III by enzyme-linked immunosorbent assays) and 
platelet activation (l~-thromboglobulin by enzyme-linked immunosorbent 
assays; P-selectin expression by flow cytometry) were assayed. Leukocyte 
activation was determined by quantitative and qualitative analysis of 
arterial filters by scanning electron microscopy in six patients from each 
group. In both circuits, thrombin values increased markedly 30 minutes 
into cardiopulmonary b pass compared with baseline values (17 < 0.001) 
(heparin-coated, 7 - 5 to 96 - 115 ng/ml; noncoated, 10 + 9 to 115 -+ 125 
ng/ml). Platelet activation as measured by /~-thromboglobulin (heparin- 
coated, 104 - 100 to 284 -- 166 IU/ml; noncoated, 81 + 74 to 288 +- 277 
IU/ml) and P-selectin expression (heparin-coated, 1.5% --. 1.5% to 6.4% - 
6.1%; noncoated, 1.4% --- 1.1% to 6.2% -+ 4.3%) also significantly increased 
30 minutes into cardiopulmonary b pass compared with baseline values 
(p < 0.001). Platelet activation and thrombin generation did not differ 
between the two circuits at any time. Granulocyte activation and platelet 
deposition did not differ between the two circuits when arterial filters were 
evaluated. Both groups had similar heparin and protamine administration, 
blood transfusions, postoperative alveolar-arterial oxygen gradient, time to 
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extubation, length of intensive care unit stay, and overall morbidity and 
mortality. Clinical outcome and blood loss did not differ between the 
groups. We conclude that heparin-coated cardiopulmonary bypass circuits 
did not improve biochemical or clinical markers of biocompatibility in a 
reoperative patient population. (J Thorac Cardiovasc Surg 1996;112:472-83) 
ardiopulmonary b pass (CPB) is associated with 
a diffuse systemic inflammatory response that 
can cause considerable morbidity, including organ 
dysfunction ;and bleeding. >s The interaction of 
blood components with the artificial surfaces of the 
bypass circuit induces contact activation of the hu- 
moral amplification system, including the comple- 
ment, kallikrein, coagulation, and fibrinolytic cas- 
cades, along with deposition and activation of 
leukocytes and platelets. Considerable fforts have 
been made to reduce the damaging effect of CPB by 
modifying the materials used in the extracorporeal 
bypass circuit. Altering the blood-contacting sur- 
faces of the extracorporeal circuit may make these 
surfaces more biocompatible, thus reducing organ 
dysfunction and perioperative morbidity. 
Early experimental and clinical studies of hepa- 
rin-coated surfaces during primary cardiac opera- 
tions have revealed less blood cell trauma, reduced 
leukocyte activation, less perioperative blood loss, 
and decreased activation of the complement cas±-- 
cades, all of which suggests improved biocompatibil- 
ity. 6-9 However, most clinical studies have excluded 
patients undergoing the high-risk procedures of 
reoperation, valve replacement, or combined coro- 
nary artery bypass grafting and valve replacement 
operation. I° Further, in other studies, 11' 12 the car- 
diotomy reservoir was not heparin-coated, introduc- 
ing a possible compounding factor. The present 
study investigated the biocompatibility of heparin- 
coated extracorporeal bypass circuits in a patient 
population undergoing reoperative coronary artery 
bypass grafting, valve replacement, or both as prac- 
ticed at a referral center for cardiovascular and 
thoracic surgery. Presumably, any clinically signifi- 
cant improvement resulting from improved biocom- 
patibility of heparin-coated systems might be height- 
ened in this population. Our study is also unique in 
that a heparin-coated cardiotomy reservoir was in- 
cluded in our treatment group such that all blood- 
contacting surfaces were heparin coated. Thus any 
biomaterial-dependent ac ivation of the body's in- 
flammatory response could not be attributed to the 
uncoated cardiotomy reservoir. 
Patients and methods 
This study involved 50 patients undergoing elective 
cardiac reoperation for coronary artery bypass grafting, 
valve operation, or both coronary artery bypass grafting 
and valve operation. Patients were selected and randomly 
assigned to the control group (n = 26) or the treatment 
group (n = 24). In the treatment group, all blood- 
contacting surfaces of the bypass circuit were heparin 
coated, except for the infusion catheters for the cardiople- 
gic solution. In the control group, an identical bypass 
circuit, including oxygenator and cannulas, was u ed but 
was not heparin-coated. The surgeons and study nurse 
were blinded as to the group assignments of the patients. 
Informed consent was obtained by a protocol approved by 
the Cleveland Clinic Foundation institutional review 
board. Inclusion criteria included all patients undergoing 
elective reoperative coronary artery bypass or valve oper- 
ation. Exclusion criteria consisted of the following: (1) 
emergency operation, (2) known coagulopathy, (3) endo- 
carditis, (4) preoperative intra-aortic balloon pump, and 
(5) inability to obtain informed consent. For randomiza- 
tion, the perfusionist drew sealed envelopes just before 
setting up the operation. 
Bypass circuits. Identical cardiopulmonary system con- 
figurations were used for both groups. However, in the 
treatment group, the circuit, the cardiotomy reservoir, and 
cannulas were heparin-coated with Duraflo II (Bentley 
Baxter Healthcare Systems, Irvine, Calif.). In both sys- 
terns, the arterial filter was heparin coated) The bypass 
system consisted of a roller-head pump, Bentley AF-1025 
arterial filter, Bentley-HSR 4000 venous reservoir and 
cardiotomy autotransfusion filter, Bentley Univox mem- 
brane oxygenator, Bentley HE-30 cardioplegic heat-ex- 
change system, Bentley BCR-3500 cardiotomy reservoir, 
RMI (Salt Lake City, Utah) aortic cannula (24F) and 
venous two-stage (36F/52F) cannula, and Bentley custom 
tubing packs. The CPB circuits were primed with 1500 ml 
of Plasma-Lyte solution (Baxter Healthcare, Deerfield, 
Ill.) and 5000 units of bovine heparin. 
All patients were premedicated with scopolamine 0.2 to 
0.4 mg and morphine 0.i mg/kg intramuscularly 1 hour 
before induction of anesthesia. Anesthesia was induced 
and maintained with a combination of fentanyl and mida~ 
zolam supplemented with isoflurane. Neuromuscular 
blockade was obtained with pancuronium or vecuronium 
titrated to effect. The total doses of fentanyl and midazo- 
lain ranged from 40 to 50 mg/kg and 60 to 80 mg/kg, 
respectively. All patients received 300 IU/kg of bovine 
heparin before aortic cannulation. Activated clotting time 
was measured with a Hemochron 801 instrument (Inter- 
national Technidyne, Edison, N.J.) and maintained at 
more than 480 seconds during the procedure with supple- 
mental heparin. 
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During CPB, patients were cooled so the rectal temper- 
ature was maintained at 28°C to 32 ° C. After aortic 
crossclamping, cold blood (4 ° C) or crystalloid cardiople- 
gic solution was used to institute rapid diastolic arrest of 
the heart. 
Our surgical strategy included the performance ofdistal 
bypass anastomoses initially whenever bypass grafting was 
part of the planned procedure. Saphenous vein anastomo- 
ses were done first then internal thoracic artery anasto- 
moses (usually to the left anterior descending coronary 
artery). Associated valve procedures were done after all 
distal coronary artery anastomoses. Proximal vein graft 
anastomosis was done while the aorta was crossclamped. 
While the patient was fully heparinized and supported 
by bypass, a cardiotomy suction device was used to return 
the shed pericardial blood to the systemic irculation. A 
cell-saving device (not heparin-coated) was used at all 
other times. Blood aspirated via the cell saving system was 
washed and not transferred until the patient had returned 
to the intensive care unit (ICU). Hematocrit value was 
maintained at 18% to 20% during bypass with blood 
transfusions. CPB was discontinued after the heart was 
deaired, provided that the bladder temperature was at 
least 36.5°C and cardiac function was good. Heparin 
effects were reversed by protamine sulfate administration 
after decannulation. 
Blood lost postoperatively was collected with indwelling 
mediastinal and pleural chest tubes and was autotrans- 
fused for the firSt 8 postoperative hours. After operation, 
packed red blood cells were transfused to maintain a 
hematocrit level of at least 25%. Platelet transfusions 
were given to patients with excessive bleeding. Fresh 
frozen plasma was administered to patients with both 
excessive bleeding and a prolonged prothrombin time. 
During this study no aprotinin was used; however, e-ami- 
nocaproic acid was used selectively before operation. 
Data collection. All data were collected by one dedi- 
cated study nurse. Preoperative patient characteristics, 
including diagnosis, preoperative aspirin or heparin use, 
age, sex, and cardiac function, were recorded. All cases 
were assessed with the Higgins Severity Score to deter- 
mine preoperative surgiCal risk. 13 Intraoperative ariables 
recorded included the number and type of bypass grafts 
done, valve procedures done, aortic crossclamp duration, 
CPB duration, blood volume administered, total heparin 
use, total protamine use, and need for e-aminocaproic 
acid. After operation, the amount of chest tube drainage 
and transfusion requirements were documented. Alveo- 
lar-arterial oxygen gradients 4 hours after admission to 
the ICU, length of assisted ventilation, and ICU length of 
Stay were also recorded. Alveolar-arterial oxygen differ- 
ence (a-aDo2) was calculated by the following equation: 
A-aDo2 = Fio2(Pstm - 47) - (Paco2 × 1.25) - Pao2 
where Fio 2 is the inspired fraction of oxygen, Paco 2 is the 
arterial carbon dioxide tension, and Pao 2 is the arterial 
oxygen tension. Because initial alveolar-arterial gradient 
after ICU admission typically is large, reflecting the effects 
of atelectasis, alveolar-arterial gradients were determined 
at 4 hours after operation. Furthermore, to standardize 
alveolar-arterial oxygen gradients to inspired fraction of 
oxygen during ventilation, respiratory indices (RI) were 
determined for each patient by the following equation: 
A-aDo2 
R I -  
Pao2 
Patients were followed up during the entire hospital stay 
for the development of complications such as periopera- 
tive myocardial infarction (creatinine phosphokinase MB 
fraction greater than 100 units with either electrocardio- 
graphic changes or hemodynamic instability), adult respi- 
ratory distress yndrome, stroke, infection, need for rein- 
tubation because of respiratory distress, or death. 
Measurements of biocompatibility indices. Plasma 
concentrations of platelet a-granule product/3-thrombo- 
globulin (/3-TG) and expression of the platelet surface 
marker P-selectin (CD 62) were measured to quantify 
platelet activation. Thrombin generation and inactivation 
by antithrombin III were measured by plasma determina- 
tion of levels of thrombin-antithrombin III (TAT III) to 
quantify the degree of stimulation to the coagulation 
system. Blood samples were obtained from an indwelling 
brachial artery catheter and analyzed according to the 
following schedule: 
1. Values obtained before skin incision, after induction of 
anesthesia, but before heparin had been given served 
as a baseline. 
2. Values obtained 30 minutes after the start of CPB were 
used to directly compare the biocompatibility of hepa- 
rin-coated surfaces and noncoated surfaces. 
3. Values obtained 5 minutes after the aortic crossclamp 
was removed were used to measure the effect of heart 
and lung reperfusion injury. 
4. Values obtained 5minutes after the reversal of heparin 
with protamine reflected the effect of the heparin- 
protamine complex formation on platelet activation 
and thrombin generation. 
The first 10 ml of blood obtained from the arterial ine 
was discarded; after plasma isolation and preparation, 
samples were stored at -70°C  until the time of assay. 
Enzyme-linked immunosorbent assays for/3-TG (Assera- 
chrom B-TG, Seine, France) and TAT III (Behring Diag- 
nostics, Westwood, Mass.) were done according to in- 
structions provided by the kit manufacturers. Surface 
expression of P-selectin (CD 62) was measured by obtain- 
ing all blood samples in a diatube (sodium citrate, aden- 
osine, theophyliine). Flow cytometry was done by placing 
a 0.1 ml aliquot of whole blood into 1.0 ml of 0.1% 
paraformaldehyde at 4°C to stop platelet activation. 
Samples were incubated at 4 ° C for 1 hour. After mixing, 
samples were washed with phosphate-buffered saline so- 
lution and stained with use of a general platelet marker 
(CD 62-P, Becton-Dickinson, San Jose, Calif.). Dual-label 
flow cytometry was done in a Becton-Dickinson FACScan 
flow cytometer with Lysis II software. Results are pre- 
sented as the percentage of platelets expressing CD 62. 
Scanning electron microscopy (SEM). In 12 patients (6 
from each group), arterial filters were analyzed by SEM to 
determine in vivo platelet and leukocyte deposition and 
activation. The samples for SEM were taken from arterial 
filter meshworks as soon as possible after CPB. The filters 
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Table I. Preoperative characteristics of patients 
undergoing CPB with heparin-coated or uncoated 
bypass circuit 
Group 
Heparin coated Uncoated 
Variable (n = 24) (n = 26) p Value 
Age (yr) 64 _+ 8 64 +_ 11 0.43 
Sex 
Male 16 22 
Female 8 4 0.13 
Hematocrit (%) 40.25 _+ 5.13 39.59 _+ 4.8i 0.66 
Left ventricular 
dysfunction 
None i2 (50%) 15 (65%) 
Mild 6 (25%) 2 (9%) 
Moderate 6 (25%) 4 (15%) 
Severe 0 1 (4%) 0.41 
Preop. aspirin 21 22 (84%) NS 
Preop. heparin 2 1 (4%) NS 
Data are expressed as mean plus or minus standard eviation or as the 
number of patients. NS, Not significant. 
first were rinsed three times with 0.1 mol/L phosphate 
buffer with 3.0% sucrose solution (pH 7.4), then rinsed 
three times With 0.9% sodium chloride. The samples 
were subsequently fixed by immersion at 4°C for 12 
hours with 2% glutaraldehyde in 0.1 mol/L phosphate 
buffer with 3.0% sucrose (pH 7.4). To obtain specimens, 
the filter cases were cut open with a bandsaw. The filter 
material was carefully extracted, and four specimens (2 
upstream and 2 downstream, each about 5 mm by 10 
mm) were cut from it. The specimens were marked with 
a cut so that the upstream and downstream orientations 
could be recognized. They were processed for SEM by 
a standard ehydration and gold-coating procedure that 
involved dehydration with a graded ethanol series and 
critical-point drying for 1 hour with liquid carbon 
dioxide. The specimens were mounted on aluminum 
studs with double-sided tape, a small amount of silver 
paint was applied around the edges, and the specimens 
were sputter-coated with gold to a final coating thick- 
ness of approximately 275 A. 
SEM was done with a JEOL JSM-T300 scanning elec- 
tron microscope (JEOL, Peabody, Mass.) as follows: 10 
fields were selected randomly from each specimen. The 
magnification factor was ×500. The field size on the 
cathode ray tube was 340/xm wide by 260/xm high, and 
the resultant area was 88,400/xm 2. Because two samples 
were obtained from the upstream and two from the 
downstream sides, a total of 40 fields was counted for each 
case. The individual field data were averaged to obtain 
values for each case: Data are reported as percent inci- 
dence divided by the fields observed ([number of obser- 
vations/number of fields] × 100). CellUlar adhesion was 
measured for all formed blood elements. Leukocyte ad- 
hesion was further analyzed as to the degree of activation. 
Leukocytes were graded as having contact, spread, or 
Table II. Procedures performed by tubing type used 
Coated Noncoated 
tubing tubing Total 
Coronary artery bypass graft 13 17 30 
AVR 2 3 5 
MVR/repair 2 1 3 
AVR/coronary artery bypass graft 2 0 2 
MVR/coronary artery bypass graft 3 2 5 
AVR/MVR 1 2 3 
AVR/MVR/coronary artery bypass 1 0 1 
graft 
AVR/aortic conduit 0 1 1 
24 26 50 Total 
AVR, Aortic valve replacement; MVR, mitral valve replacement. 
degranulation, depending on the degree of leukocyte 
activation seen according to the criteria of Marchant, 
Miller, and Anderson. 14 The microscopists were unaware 
of the CPB circuit types used and the patient group 
assignment. 
Statistical analysis. Data are presented as mean plus 
or minus standard eviation of the mean. Categorical data 
were analyzed by Fisher's exact test. The nonparametric 
Wilcoxon rank-sum test was used to determine whether 
the distributions of  continuous variables differed between 
the two groups. For variables measured over time (hemo- 
static indices and ventilator weaning), repeated-measures 
analysis of variance with orthoganol polynomial trend was 
used. Significance was set at p < 0.05. 
To exclude any error induced by procedure done, the 
patients undergoing only coronary artery bypass grafting 
were analyzed separately. 
Arterial filters were compared between the two sub- 
groups. Total cell counts on the upstream and down- 
stream sides were compared separately between groups. 
Within each group, the upstream and downstream sides 
were compared for differences in effectiveness of the 
arterial filter. 
Results 
Patient characteristics. All preoperative patient 
characteristics, including age, sex, heart function, pre- 
operative aspirin use, and heparin use were similar for 
the two groups. Both treatment groups had similar 
preoperative risk scores (Table I). The types of proce- 
dures done were similar in each group (Table II). 
Intraoperative patient care characteristics are 
shown in Table III. Both groups had similar CPB 
and crossclamp times and similar procedures done. 
Heparin use, protamine use, and e-aminocaproic 
acid use, as well as the mean number of grafts done, 
were likewise similar between groups. Intraopera- 
tive blood transfusion requirements did not differ 
between the two groups. 
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Table IIL [ntraoperative patient characteristics 
compared by type of bypass used 
Group 
Heparin coated Uncoated p 
(n = 24) (n = 26) Value 
Bypass time (min) 128.5 -+ 46.0 121 _+ 42.5 0.57 
Crossclamp time 85.6 -+ 34.0 78.3 -+ 31.1 0.43 
(min) 
Procedures 
Isolated CABG 13 (54%) 17 (65%) 
CABG with valve 6 (25%) 3 (12%) 
Isolated valve 5 (21%) 6 (23%) 
Heparin (units) 30,500 +- 6,685.5 30,308 _+ 6,583 0.83 
Protamine (mg) 409.6 -+ 198.5 356.0 _+ 157.0 0.40 
e-Aminocaproic a id 12 11 0.39 
(No. of pts. given) 
Number of grafts 2.17 -- 1.01 1.96 _+ 1.0 
(mean _+ SD) 
Transfused blood 2.8 -+ 2.1 2.5 _+ 4.3 0.15 
(units) 
Higgins Severity 7.04 -+ 2.5 6.19 _+ 2.8 0.26 
Score 13 
CABG, Coronary artery bypass grafting; SD, standard eviation. 
Postoperative patient characteristics are shown in 
Table IV. Both groups had a similar number of units 
transfused per patient and a similar number of 
patients who required no transfusion. The two 
groups had similar amounts of chest tube drainage, 
and no difference was found in the time to extuba- 
tion or the postoperative alveolar-arterial oxygen 
gradients or respiratory indices. Length of ICU stay 
was also similar between the two groups (Table IV). 
Two patients died postoperatively. In the noncoated 
group one patient died of respiratory insufficiency, 
adult respiratory distress yndrome, and subsequent 
lung infection. One patient in the heparin-coated 
group died of cardiac failure that had occurred 
intraoperatively. The morbidity rate was similar 
between the two groups. No patients required ex- 
ploration for bleeding, and only one patient re- 
quired reintubation i the heparin-coated group; the 
prevalence of myocardial infarction was greater in 
the heparin-coated group, but the difference was not 
statistically significant (Table V). 
Immunoassay results in all patients 
TAT IlL Plasma TAT III levels increased sig- 
nificantly (p < 0.001) during bypass compared 
with baseline values. The levelS continued to 
increase 5 minutes after the crossclamp was re- 
leased and 5 minutes after protamine was admin- 
istered (Fig. 1). No difference was found between 
the heparin-coated and the noncoated groups. 
The variation between patients was large with 
respect to thrombin generation at times other 
than baseline. 
[3- TG levels. 13-TG release increased significantly in 
both treatment groups at 30 minutes after CPB was 
started (p < 0.01)./3-TG levels continued to increase 5
minutes after the crossclamp was released. No further 
increase was noted in the heparin-coated group after 
protamine was given (Fig. 2); however,/3-TG levels did 
increase in the uncoated group after protamine was 
given. A large variation was seen between patients in 
each group 30 minutes after CPB was begun and at 
each subsequent interval. 
P-selectin expression. CD 62 receptor expression 
increased significantly over baseline in both groups 
after 30 minutes of CPB (p < 0.01). No further 
increases occurred after crossclamp release or after 
protamine administration (Fig. 3), and these values 
did not differ significantly between groups. Again, 
variation was large between patients in each group. 
Arterial filter analysis. The preoperative charac- 
teristics of the 12 patients in whom arterial filters 
were analyzed were similar with respect o age, sex, 
heart function, surgical risk, aspirin use, and previ- 
ous electrocardiogram findings. They demonstrated 
no difference in bypass time, crossclamp time, hep- 
arin use, protamine use, e-aminocaproic acid use, 
procedures done, blood transfusion requirements, 
chest tube drainage, or ICU length of stay. 
The total cell disposition was similar in the hep- 
arin-coated and uncoated groups, on both filter 
sides (Table VI). Similar amounts of cellular and 
proteinaceous deposition were seen on the coated 
and noncoated systems regardless of which side of 
the arterial filter was analyzed. Platelet deposition 
was less on the "up" side of the heparin-coated 
filters, but this difference was not statistically signif- 
icant. As in the other analyses, variation between 
patients was large (Table VI). 
Length of time of CPB was analyzed between the 
two bypass circuits and the side of filter analyzed. 
No correlation between length of time of CPB and 
degree of total cell adhesion or leukocyte activation 
was found. 
There was no difference in the number of leukocytes 
adhering to the filter or in the degree of activation as 
measured by contact, spread, or degranulation. 14 In 
general, the amount of leukocyte contact activation 
was low, but variation between patients was large. 
Fig. 4 demonstrates, by photomicrographs, the 
degree of variability between the groups. Interpa- 
tient variability within groups was also large. 
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Table IV. Postoperative patient characteristics 
Group 
Heparin coated 
(n = 24) 
Uncoated 
(n = 26) p Value 
ICU blood transfusion (units) 0.8 + 1.3 
CT drainage 644.0 -+ 354.4 
Time to extubation 
-<1 day 22 (91.7%) 
->2 days 2 (8.3%) 
Blood usage amount 
OR 
No blood 5 (21%) 
1 unit 4 (17%) 
>1 unit 15 (62%) 
ICU 
No blood 16 (67%) 
1 unit 2 (8%) 
>1 unit 6 (25%) 
No. (%) of patients receiving no blood 4 (16.7%) 
ICU LOS (days) 2.04 _+ 1.0 
Days in ICU 
1 day 8 (33%) 
2 days 10 (42%) 
>2 days 6 (25%) 
Time to extubation (isolated CABG only) 15.6 + 9.1 
->2 days (%) 
Alveolar-arterial O 2 gradient at 4 hr (mm Hg) 145.6 + 103.4 
Respiratory index 0.46 + 0.15 
1.2 +- 1.8 
796.7 -+ 813.8 
23 (88.5% 
3 (11.5% 
10 (39%) 
3 (11%) 
13 (50%) 
15 (57%) 
2 (8%) 
9 (35%) 
7 (26.9%) 
2.69 _+ 2.50 
10 (39%) 
6 (23%) 
10 (39%) 
20.8 + 9.5 
153.0 -+ 87.9 
0.46 _+ 0.16 
0.49 
0.985 
0.999 
0.455 
0.820 
0.382 
0.175 
0.342 
0.090 
0.78 
0.92 
CT, Chest tube; OR, operating room; LOS, length of stay; CABG, coronary artery bypass grafting. 
Immunoassay results: patients having coronary 
artery bypass grafting only. For patients undergo- 
ing coronary bypass grafting only (n = 30; n = 13 in 
the heparin-coated group and n = 17 in the non- 
coated group), results were analyzed separately to 
eliminate potential confounding surgical factors re- 
lated to valve replacement. This separate analysis 
also allowed for comparison with other studies in 
the literature, which typically analyzed only patients 
with bypass grafting. 15-~7 
TAT III. Plasma TAT III levels increased signifi- 
cantly (p < 0.001) during bypass in the noncoated 
group. This increase was present but much less 
pronounced in the heparin-coated group. Throm- 
bin generation occurred after crossclamp release, 
but little additional thrombin was generated after 
protamine administration. The coated and non- 
coated groups did not differ throughout the sam- 
pling period because of the large individual vari- 
ations in response to CPB itself. These results 
were similar to those for patients undergoing 
valve operation or valve operation and bypass 
grafting (data not shown). 
Table V. Postoperative morbidity and mortality after 
CPB with heparin-coated or uncoated bypass circuit 
Group 
Heparin coated Uncoated p 
(n = 24) (n = 26) Value 
Morbidity 
Bleeding 0 (0%) 2 (8%) 0.49 
Respiratory failure 1 (4.2%) 4 (15%) 0.35 
Myocardial infarction 3 (13%) 0 (0%) 0.10 
Cerebral vascular 0 (0%) 1 (4%) 0.99 
accident 
Sepsis 0 (0%) 0 (0%) --  
IABP use 2 (8%) 0 (0%) 0.26 
Mortality 1 (4%) 1 (4%) 0.99 
IABP, Intraaortic balloon pump. 
[3-TG levels. ]3-TG release increased significantly 
in both groups after CPB was begun (p < 0.01). 
/3-TG levels continued to increase after crossclamp 
release. /3-TG levels decreased in the heparin- 
coated group after protamine was given but contin- 
ued to increase in the noncoated group. Although 
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Fig. 1. Plasma TAT III levels are shown measured at four times during cardiac procedure in all 50 
patients. Plasma levels increased in both groups in similar fashion after initiation of CPB, after crossclamp 
(X-clamp) was released, and slightly after protamine was given. There was no difference statistically 
between two groups. 
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Fig. 2. Serum levels of J3-TG release are shown from stimulated platelets at four times during cardiac 
procedure in all 50 patients./3-TG levels increased 30 minutes into bypass and after crossclamp (X-clamp) 
was released and in non-heparin-coated group continued to increase after protamine was given. No further 
increase was seen after protamine administration i heparin-coated group. There was no difference 
between two groups. 
platelet activation appeared greater in the heparin- 
coated group throughout bypass, there was no dif- 
ference between the two groups. These results mir- 
rored the results seen in the full study groups. 
P-selectin expression. CD 62 receptor expression 
increased significantly over baseline values in both 
groups after 30 minutes of CPB (p < 0.01). Little 
additional increase in platelet activation was seen 
after crossclamp release or after protamine ad- 
ministration. CD 62 receptor expression did not 
differ significantly between the two groups largely 
because of individual variations in response dur- 
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Fig. 3. Platelet marker CD 62 expression is shown at four times during cardiac surgical procedure. CD 62 
receptor expression (P-selectin) was similar between heparin-coated and non-heparin-coated groups and 
increased markedly 30 minutes into bypass; however, no further increases were seen. There was no 
difference between two groups. 
Table Vl. Deposition of blood coagulation components on upstream and downstream sides of arterial filters in 
12 patients 
Filter type and side Leukocytes Platelets RBCs Protein 
Uncoated circuit filters 
(n = 6) 
Upstream side 2.14 _+ 3.93 4.29 _+ 6.07 0.00 _+ 0.00 4.29 _+ 9.32 
Downstream side 1.43 _+ 2.44 2.14 _+ 2.67 1.43 -+ 2.44 3.57 -+ 5.56 
Heparin-coated circuit filters 
(n - '5 )  
Upstream side 5.00 +_ 10.00 0.83 + 2.04 0.83 -+ 2.04 4.17 -+ 10.21 
Downstream side 1.67 -+ 2.58 1.67 +_ 4.08 0.00 _+ 0.00 1.67 _+ 4.08 
Deposition is expressed as percent incidence: (number of component observations + number of SEM fields) × 100. Values given as mean plus or minus 
standard eviation. There was no significant difference between the groups tested or between the different sides of the arterial filters tested. RBCs, Red blood 
cells. 
ing bypass. These results are similar to those seen 
in the entire study group. 
Discussion 
We found that in patients undergoing reoperative 
coronary artery bypass or valve procedures the 
heparin-coated CPB circuit had no significant clini- 
cal or biochemical benefit over the standard un- 
coated circuit when a single crossclamp technique 
was used and pericardial blood was continuously 
returned to the bypass circuit. Both groups had 
similar preoperative and intraoperative characteris- 
tics, which makes it unlikely that any differences in
duration Of bypass, crossclamp times, patient char- 
acteristics, or procedures done affected the results. 
Measurements of biocompatibility, including plate- 
let activation, thrombin formation, and granulocyte 
activation, were done over the course of CPB and 
found not to differ between groups. Moreover, both 
groups had similar clinical outcomes with respect to 
duration of ventilation, alveolar-arterial oxygen gra- 
dient, blood loss, and transfusion requirements. 
However, given the limited number of patients in 
this study, the possibility of a type II error must be 
recognized. 
Our study demonstrated several results unique to 
patients undergoing reoperative cardiac procedures. 
Thrombin generation occurred early in the bypass 
period and platelet stimulation occurred throughout 
the period of bypass, which has not been demon- 
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Fig. 4. SEM photomicrographs of arterial line filters demonstrating intragroup variability. A, Marked 
leukocyte adherence in noncoated group. B, Minimal leukocyte adherence in noncoated group. C, Marked
leukocyte adherence to filter in heparin-coated group. D, Minimal leukocyte adherence in heparin-coated 
group. 
strated before in patients undergoing primary or 
reoperative cardiac surgical procedures. Further- 
more, our study revealed a tremendous individual 
patient variation in response to cardiac reoperation. 
This was consistently seen in both the biochemical 
markers of biocompatibility and on SEM evaluation 
of leukocyte activation. Wagner and associates 11 
looked at similar indices of thrombin and platelet 
activation in patients undergoing primary coronary 
artery bypass grafting with use of an uncoated 
cardiotomy reservoir and found that platelet activa- 
tion occurred early during bypass but did not in- 
crease with aortic crossclamp release. Moreover, 
thrombin was not generated during bypass but was 
generated only after crossclamp release. It is likely 
that the early rise we observed in both platelet 
activation and thrombin generation represents bo h 
biomaterial-dependent a d biomaterial-indepen- 
dent stimulation of platelets and the body's coagu- 
lation system. 
Our finding of early thrombin generation during 
bypass and continued platelet activation after cross- 
clamp release is likely related to biomaterial-inde- 
pendent factors such as our surgical technique and 
reoperative patient population. Our study design 
allowed for the free aspiration of shed pericardial 
blood throughout the CPB procedure, which may 
stimulate the body's defense system substantially. 
Tabuchi and associates 17 have shown that the peri- 
cardial cavity stimulates blood components that 
come in contact with the cavity during CPB. Fur- 
thermore, blood aspirated from the pericardial sac 
had a heparin concentration that was only 20% of 
that in the completely heparinized systemic ircula- 
tion. Moreover, thrombin levels and fibrin degener- 
ative products were 40 times higher in blood aspi- 
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rated from the pericardium than in blood in the 
bypass circuit. When reinfused blood collected from 
the pericardial cavity was placed back into the 
bypass circuit, thrombin production and fibrinolysis 
significantly Jincreased in the systemic blood. These 
investigators concluded that tissue factor and tissue- 
type plasminogen activator accelerate activation of 
clotting and subsequently fibrinolysis in the pericar- 
dial cavity. 17 This local activation contributes greatly 
to the systemic activation, affecting hemostasis dur- 
ing CPB. Tissue factor is a strong stimulus of the 
extrinsic clotting system, 18 and tissue-type plasmin- 
ogen activator activates the fibrinolytic system. 19' 2o 
De Haan and colleagues 21similarly demonstrated 
that retransfusion of activated pericardial blood 
during CPB clinically impairs hemostasis and exac- 
erbates bleeding. Most likely, patients with abun- 
dant pericardial adhesions who are undergoing re- 
operation produce even greater tissue factor and 
tissue-type plasminogen activation than patients un- 
dergoing primary cardiotomy. The greater dissec- 
tion involved[ with reoperation presumably produces 
a tremendous, yet variable biomateriaMndependent 
stimulation of the body's defense mechanisms that 
overwhelms any biomaterial-dependent benefit of 
heparin-coated tubing of the extracorporeal circuit. 
Although we were unable to demonstrate im- 
proved biocompatibility in our patients undergoing 
reoperation, this does not mean that heparin-coated 
tubing is not biocompatible. Other investigators 
have shown improved biocompatibility of heparin- 
coated extracorporeal bypass circuits when aspi- 
rated pericardial blood is not returned to the sys- 
temic circulation. 1°' 15, 22 Typically, a red blood cell 
washing device is used to aspirate all pericardial 
blood, which is washed, centrifuged, and returned to 
the patient after operation. Fosse and associates 16
found that complement activation and granulocyte 
stimulation were reduced in heparin-coated CPB 
circuits compared with findings in noncoated cir- 
cuits. Pradham and colleagues 12have also shown 
that thrombin generation is significantly less (as 
measured by TAT III) in heparin-coated CPB cir- 
cuits when cardiotomy suction is avoided. Neither 
Fosse and colleagues 16 nor Pradham and col- 
leagues 12 found a reduction in chest tube drainage 
or blood transfusion requirement in patients treated 
with heparin-coated surfaces. There are, however, 
drawbacks to collecting shed pericardial blood and 
not retransfusing this blood at the time of operation. 
The use of a cell-saving device in lieu of cardiotomy 
suction is more expensive, and procedures with 
potential for extensive blood loss or that necessitate 
extensive deairing may not be suitable for heparin- 
coated systems without cardiotomy aspiration capa- 
bility. This may even increase the need for blood 
transfusions. Furthermore, it is unlikely that the 
cardiotomy reservoir itself is the cause of these 
changes, inasmuch as in our study the cardiotomy 
reservoir was heparin-coated. It is likely that our 
surgical population and technique allowed biomate- 
riaMndependent s imulation of the body's defense 
system to overwhelm any biomaterial-dependent 
mitigating properties of heparin-coated tubing. 
The tremendous variability in individual patient 
responses to reoperative cardiac procedures was 
also demonstrated byanalysis of arterial ine filters. 
Moreover, our analysis of arterial ine filters, which 
were heparin-coated in both groups, did not show a 
difference in total cell adhesion, platelet activation, 
or granulocyte activation between the two groups 
regardless of the side of the arterial filter evaluated. 
SEM is a reliable method for measuring leukocyte 
activation and fibrin deposition in vivo because it 
avoids in vitro contact activation, which is inherent 
in other methods. 14 In general, variation was large 
within the two study groups, which may reflect the 
large variation in patient response to reoperative 
CPB. Borowiec and associates 8 also found no differ- 
ence between coated and uncoated CPB circuits 
when heparin-coated arterial filters were used in 
both study groups. Similarly, individual variability 
was high in this study. However, when uncoated 
filters were used, cell adhesion and activation dif- 
fered significantly, which was believed to be caused 
by local filter activation of these blood components. 
For this reason, all arterial filters currently sold by 
Baxter Bentley are heparin-coated regardless of the 
rest of the bypass circuit. The large variation in 
platelet and leukocyte activation seen in our study 
supports the theory that individual patients respond 
differently and in varying degrees to the damaging 
effects of CPB and that other biomaterial-indepen- 
dent factors determine the degree of whole-body 
inflammatory response observed uring CPB. Our 
results also suggest hat this individual variation in 
inflammatory response is independent of the length 
of time of CPB. 
To achieve clinical benefit from heparin-coated 
bypass circuits, several changes may be required in 
the way CPB is performed, including reducing sys- 
temic heparinization and avoiding aspiration of 
pericardial blood into the systemic irculation in an 
effort to reduce blood loss and complement activa- 
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tion. Von Segesser and colleagues 1°' 22 have shown 
that heparin-coated bypass circuits are safe with one 
third of the standard heparin dose (1 mg/kg) when 
all pericardial blood is collected with a cell-saving 
device and is not rein fused systemically. Patients in 
whom heparin-coated bypass circuits were used 
required less protamine and fewer blood transfu- 
sions; also a lower percentage of patients required 
transfusion. Pekna and associates, 15 with use of a 
similar educed ose of systemic heparinization and 
a fully coated bypass system, found significantly 
reduced complement activation. This finding may, 
however, have been partially a result of the use of 
less protamine to reverse the lower systemic dose of 
heparin in the heparin-coated group because hepa- 
rin-protamine complexes activate complement and 
platelets. 23Nonetheless, use of less protamine may 
be an advantage. Some investigators have criticized 
reducing systemic heparinization with heparin- 
coated bypass circuits because of the increased risk 
of thrombin generation and fibrin microemboli. 24
Heparin does not prevent hrombin generation but 
rather potentiates the neutralizing effect of anti- 
thrombin III after thrombin is formed. Therefore 
the potential for clot formation may actually be 
increased. Cheung and colleagues 25have reported 
intracardiac lot formation when heparin-coated 
bypass circuits were used with reduced systemic 
heparinization (1mg/kg). We also have reported an 
increased prevalence of intracardiac clot formation 
in patients maintained on extracorporeal life sup- 
port with use of a heparin-coated circuit without 
systemic heparinY Clearly, further research is re- 
quired to determine the safest strategy for use of 
heparin-coated bypass circuits in cardiac operations. 
In conclusion, we found no benefit o the use of 
heparin-coated xtracorporeal bypass circuits in pa- 
tients undergoing reoperative cardiac procedures 
when similar doses of systemic heparinization were 
used in both groups with constant return of pericar- 
dial aspirated blood returned to the systemic ircu- 
lation. However, these results must be interpreted 
cautiously because of the small sample size. Appar- 
ently, many biomaterial-independent stimulants to 
the whole-body inflammatory response occur at 
various times during bypass that may be more 
pronounced in patients undergoing reoperation. 
Fundamental changes in the way CPB is done are 
likely to be required to demonstrate he benefit of 
heparin-coated circuits in patients undergoing a
variety of reoperative procedures. Not returning 
pericardial blood to the systemic irculation, limit- 
ing heart and lung reperfusion injury, and using 
specific priming solutions a7' 28 and perhaps anti- 
inflammatory drugs may all be needed to elucidate 
the beneficial effects of biomaterial-dependent acti-
vation of the body's inflammatory response. Such 
major changes in the way CPB is done may limit the 
usefulness of heparin-coated circuits in patients 
undergoing reoperation, 
We thank Sharon Grechny for help in preparing this 
manuscript and Shelly Sapp, PhD, for her statistical 
analysis, as well as Mary Sitz for data collection. 
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